The F11 Receptor (F11R)/Junctional Adhesion Molecule-A (JAM-A) (F11R/JAM-A) in cancer progression

Kamila Czubak-Prowizor1 · Anna Babinska2 · Maria Swiatkowska1

Received: 5 February 2021 / Accepted: 8 September 2021 / Published online: 17 September 2021
© The Author(s) 2021

Abstract
The F11 Receptor (F11R), also called Junctional Adhesion Molecule-A (JAM-A) (F11R/JAM-A), is a transmembrane glycoprotein of the immunoglobulin superfamily, which is mainly located in epithelial and endothelial cell tight junctions and also expressed on circulating platelets and leukocytes. It participates in the regulation of various biological processes, as diverse as paracellular permeability, tight junction formation and maintenance, leukocyte transendothelial migration, epithelial-to-mesenchymal transition, angiogenesis, reovirus binding, and platelet activation. Dysregulation of F11R/JAM-A may result in pathological consequences and disorders in normal cell function. A growing body of evidence points to its role in carcinogenesis and invasiveness, but its tissue-specific pro- or anti-tumorigenic role remains a debated issue. The following review focuses on the F11R/JAM-A tissue-specific manner in tumorigenesis and metastasis and also discusses the correlation between poor patient clinical outcomes and its aberrant expression. In the future, it will be required to clarify the signaling pathways that are activated or suppressed via the F11R/JAM-A protein in various cancer types to understand its multiple roles in cancer progression and further use it as a novel direct target for cancer treatment.

Keywords 
Tight junction · Junctional Adhesion Molecule-A · JAM-A · F11-receptor · F11R/JAM-A · Cancer progression

Abbreviations
AF-6 Afadin
AJ(s) Adherens junction(s)
AMOT Angiomotin
AP1 Activator protein 1
aPKC Atypical protein kinase C
ATC Anaplastic thyroid carcinoma
bFGF Fibroblast growth factor
BM-EC(s) Bone marrow-derived endothelial cell(s)
BVES Blood vessel epicardial substance
CAM(s) Cell adhesion molecule(s)
CAR Coxsackievirus and adenovirus receptor
CASK Calcium/calmodulin-dependent serine protein kinase
CDK4 Cyclin-dependent kinase 4
CLMP CAR-like membrane protein
Crb3 Protein crumbs homolog 3
EMT Epithelial-to-mesenchymal transition
EOC Epithelial ovarian cancer
ERK Extracellular signal-regulated kinase
ESAM Endothelial cell-selective adhesion molecule
F11R F11-receptor
GBM Glioblastomas
GEF-H1 Guanine nucleotide exchange factor H1
GI(s) Gap junction(s)
GSK3 α/β Glycogen synthase kinase 3, α and β isoforms
HER2 Human epidermal growth factor receptor-2
HGSC High-grade serous carcinoma of uterine adnexa

✉ Kamila Czubak-Prowizor
kamila.czubak-prowizor@umed.lodz.pl

1 Department of Cytobiology and Proteomics, Medical University of Lodz, 6/8 Mazowiecka St., 92-215 Lodz, Poland

2 Department of Medicine, State University of New York Downstate Medical Center, 450 Clarkson Ave, Brooklyn, NY 11203, USA
| **HNSCC** | Head and neck squamous cell carcinoma |
| **HSC(s)** | Hematopoietic stem cells |
| **huASH1** | Human absent small and homeotic discs protein 1 homolog |
| **IgSF** | Immunoglobulin superfamily |
| **JACOP** | Junction-associated coiled-coil protein |
| **JAM(s)** | Junctional adhesion molecule(s) |
| **JAM-A** | Junctional adhesion molecule-A |
| **JEAP** | Junction-enriched and-associated protein |
| **JNK** | C-Jun N-terminal kinase |
| **LFA-1** | Leukocyte function-associated antigen-1 |
| **LYRIC** | Lysine-rich CEACAM1 co-isolated protein |
| **MAGI** | Membrane-associated guanylate kinase with inverted orientation |
| **MAPK** | Mitogen-activated protein kinase |
| **MarcelD3** | MARVEL domain-containing protein 3 |
| **MEK** | Serine/threonine/threonine kinase |
| **MM** | Multiple myeloma |
| **MUPP1** | Multi-PDZ domain protein 1 |
| **NFkB** | Nuclear factor kappa B |
| **NPC** | Nasopharyngeal carcinoma |
| **NSCLC** | Non-small cell lung cancer |
| **OED** | Oral epithelial dysplasia |
| **OSCC** | Oral squamous cell carcinoma |
| **Pals1** | MAGUK p55 subfamily member 5 |
| **PAR-3** | Partitioning-defective 3 homolog |
| **PATJ** | Pals1-associated tight junction protein |
| **PI3K/Akt** | Phosphoinositide 3-kinase/protein kinase B |
| ** PICK-1** | Protein interacting with C kinase 1 |
| **PILT** | Protein incorporated later into tight junctions |
| **PP** | Protein phosphatase |
| **PTEN** | Phosphatase and tensin homolog |
| **Rab** | Ras-related protein Rab |
| **RAF** | Serine/threonine-protein kinase |
| **RAPGEF2/PDZ-GEF1** | Rap guanine nucleotide exchange factor 2 |
| **RAPGEF6/PDZ-GEF2** | Rap guanine nucleotide exchange factor 6 |
| **RAS** | Small GTPase |
| **RCC** | Renal cell carcinoma |
| **RPTPβ** | Receptor-type tyrosine-protein phosphatase β |
| **SGT(s)** | Salivary gland tumor(s) |
| **TAZ** | Transcriptional coactivator with PDZ-binding motif |
| **Tuba** | Tubulin alpha-1A chain |
| **TEM** | Transendothelial migration |
| **TGF-β** | Transforming growth factor-β |
| **TI(s)** | Tight junction(s) |
| **WNK4** | Serine/threonine-protein kinase WNK4 |
| **YAP** | Yes-associated protein |
| **Yes** | Tyrosine-protein kinase Yes |
| **ZO** | Zonula occludens |
| **ZONAB** | ZO-1-associated nucleic-acid binding protein |

### Introduction

Intercellular interactions are fundamental for the development and function maintenance of multicellular organisms through the regulation of physiological events, such as tissue barrier formation, tissue integrity regulation, or inflammatory cell recruitment regulation [1–3]. Cells accommodate to changes occurring in their microenvironment due to the information transmitted by adhesion receptors on neighboring cells, which regulate receptor-mediated cellular interactions through participation in the signal transduction pathways [1, 4, 5]. These receptors use their cytoplasmic domains that often contain specific motifs (including proline-rich motifs, phosphorylation sites, FERM and PDZ domain-binding motifs) to interact with appropriate specific interaction motifs in cytoplasmic proteins (SH3, Src-homology-3; SH2, Src-homology-2; FERM or PDZ domains, respectively) [6–9].

Cell–cell adhesion and contact between adjacent cells take place through multiprotein complexes located in intercellular junctions. In vertebrates, these cellular structures mostly comprise adherens junctions (AJs), gap junctions (GJs), desmosomes, and tight junctions (TJs) [10–15]. The latter ones are dynamic structures that are distributed at the most apical end of the lateral endothelial and epithelial cell membrane and establish two barrier types, such as a paracellular diffusion barrier (the ‘gate’ function) and an intramembrane diffusion barrier (the ‘fence’ function). TJs as paracellular gates are responsible for the selective permeability of water, solutes, ions, and small molecules that perform a critical role in the tissue and organ homeostasis maintenance. The second type of barrier limits the membrane component replacement among the apical and basolateral cell surface domains that have an impact on apicobasal cell polarity regulation [3, 10, 12, 14, 16]. Furthermore, TJs also play an essential role as a bidirectional signaling platform [12, 16] that regulates various cellular processes,
such as proliferation, differentiation and polarization of cells [17–22], cellular stress response [23], gene expression [24], and the cytoskeleton [14, 25, 26]. Structurally, TJs mainly consist of adaptor proteins, transcriptional and post-transcriptional regulators, transmembrane and signaling proteins [10, 12, 16, 17, 27–32] (Fig. 1 summarizes the key tight junction-associated proteins). In numerous human diseases, particularly in inflammatory disorders, tumor progression, and cancer metastasis, TJ disturbances are observed [13, 30, 33–47].

Junctional adhesion molecules (JAMs) are cell adhesion molecules (CAMs) of the immunoglobulin superfamily (IgSF), which are mainly located in epithelial and endothelial cell intercellular junctions [48] and also expressed on circulating platelets [49] and leukocytes [49, 50]. A variety of biological processes are regulated by the JAMs’ ability to trigger intracellular cascades of signals at intercellular contact sites, including the regulation of leukocyte diapedesis, TJ formation and maintenance, paracellular permeability, cell polarization, barrier function regulation, cell migration, and platelet activation [1, 4, 27, 51–53]. The following review focuses on the current knowledge about the F11R/JAM-A protein, especially its tissue-specific involvement in tumorigenesis and metastasis. We also discuss the correlation between poor cancer patient clinical outcomes and aberrant F11R/JAM-A expression.

### F11R/JAM-A structure, localization, and function

The first discovered member of the junctional adhesion molecule family was F11R/JAM-A (currently also known as JAM, JAM-1, F11R, CD321) [27, 48, 54–57]. Initially, this protein was described as the human platelet F11 receptor for a monoclonal antibody called mAb.F11, which induces platelet activation [54, 55] and later as an adherens and tight junction protein [48, 58]. F11R/JAM-A is a transmembrane glycoprotein that consists of a short C-terminal cytosolic tail, a single transmembrane segment, and an extracellular N-terminal region that contains two Ig-like domains (Fig. 2a) [27, 29, 48, 52, 54, 58, 59]. The cytoplasmic tail is composed of 40 amino acid residues, contains phosphorylation sites and the C-terminal PDZ (PSD-95/Discs-large/ZO-1 [15, 31, 60–62]) domain-binding motif (-SSFLV COOH) which mediates direct protein interactions [57]. F11R/JAM-A is expressed by various cell types and tissues, among other endothelial and epithelial cells [48], platelets [55], leukocytes [49, 50], hematopoietic stem cells (HSC) [63], glial cells [64], spermatozoa and Sertoli cells [65, 66], heart [58], intestine [67], kidney [58], liver [58], lung [58], and lymphoid organs [68, 69] (distribution and functions are summarized in

**Fig. 1** Key components of tight junctions (TJs). Tight junctions are composed of four main protein classes: transmembrane, adaptor, signaling, and transcriptional and post-transcriptional regulators. Diagram illustrates key proteins associated with TJs; it is not a full list of proteins presented in this cell structure. AMOT angiomotin, AP1 activator protein 1, aPKC atypical protein kinase C, BVES blood vesel epicardial substance, CAR coxsackievirus and adenovirus receptor, CDK4 cyclin-dependent kinase 4, CRB3 protein crumbs homolog 3, ESAM endothelial cell-selective adhesion molecule, GEF-H1 guanine nucleotide exchange factor H1, huASH1 human absent small and homeotic discs protein 1 homolog, JACOP junction-associated coiled-coil protein, JAMs junctional adhesion molecules, JEAP junction-enriched and -associated protein, LYRIC lysine-rich CEACAM1 co-isolated protein, MAGI membrane-associated guanylate kinase with inverted orientation, MarcelD3 MARVEL domain-containing protein 3, MUPP1 multi-PDZ domain protein-1, Pals1 MAGUK p55 subfamily member 5, PAR partitioning defective, PATJ Pals1-associated tight junction protein, PILT protein incorporated later into tight junctions, PP protein phosphatase, PTEN phosphatase and tensin homolog, Rab Ras-related protein Rab, RPTPβ receptor-type tyrosine-protein phosphatase β, TAZ transcriptional coactivator with PDZ-binding motif, Tuba tubulin alpha-1A chain, WNK4 serine/threonine-protein kinase WNK4, YAP Yes-associated protein, Yes tyrosine-protein kinase Yes, ZO zonula occludens, ZONAB ZO-1-associated nucleic-acid binding protein
Table 1). Of note, its functions depend on sequence motifs, i.e., adhesive activity is regulated by extracellular domain motifs, whereas the cytoplasmic domain motifs adjust scaffolding and signaling protein interactions. Predictably, F11R/JAM-A contributes to the regulation of the variety of cellular processes, as diverse as epithelial/endothelial barrier function [30, 67, 70, 71], transendothelial migration of leukocytes (TEM) [48, 72–76], hemostasis [77–79], angiogenesis [80–82], hematopoiesis [83], the male germ cell [65, 84] and central nervous system [85] development, immune homeostasis and inflammation [86], the epithelial-to-mesenchymal transition (EMT) [87, 88], intercellular junction assembly [89, 90], cell migration regulation [57, 61, 81, 91], platelet aggregation [54, 92] and adhesion [92, 93], cell adhesion [30], and reovirus binding [94, 95]. Furthermore, it was proven that F11R/JAM-A is involved in the development of several pathologies, such as cardiovascular diseases [96–99], inflammatory bowel disease [100], rheumatoid arthritis [101], neurological disorders [72, 102], reovirus infection [94, 103, 104], and various cancer types [66, 87, 88, 105–142].

**F11R/JAM-A extracellular domain**

The extracellular domain of F11R/JAM-A consists of the distal Vᵢ₄-type Ig-like domain (D1 domain, S₂₈–K₁₂₅) involved in homophilic binding and membrane-proximal C₂-type Ig-like domain (D2 domain, P₁₃₅–R₂₂₈) participating in heterophilic interactions with the leukocyte αLβ₂ integrin (LFA-1, leukocyte function-associated antigen-1; CD11a/CD18 [143]) and reovirus protein σ1 (σ1 ligand) [27, 29, 52, 59–61, 90, 93, 144, 146–148]. The D1 domain has two structural motifs, i.e., the **cis**-dimerization motif (R₅₉Vₑ₆₁) and **trans**-dimerization motif (N₄₃N₄₅P₄₅), and the D2 has a single N-glycan at N₁₈₅ residue. The cytoplasmic region includes phosphorylation sites (Y₂₈₀, S₂₈₄) and the type II PDZ domain-binding motif (–F₂₉₇L₂₉₈V₂₉₉–COOH). In the **cis**-dimerization process, two F11R/JAM-A molecules on the same cell form an inverted U-shaped homodimer by salt bridges between two oppositely charged amino acid residues (Eₑ₆₁⋯R₅₉; R₅₉⋯Eₑ₆₁). The N₄₃N₄₅P₄₅ motif participates in the **trans**-homophilic binding of two F11R/JAM-A **cis**-dimers on opposing cells. Likely, uncharged, polar residues (N₄₃⋯N₄₅; N₄₃⋯N₄₅) mostly mediate in **trans**-dimerization.
leukocyte integrin αLβ2 binding [73], and reovirus protein σ-1 attachment [94, 95].

**F11R/JAM-A cytoplasmic domain**

F11R/JAM-A directly associates with proteins through the C-terminal type II PDZ domain-binding motif (–F297L298V299–COOH), which is localized in the cytoplasmic domain (Fig. 2a) [4, 57, 150]. All proteins called direct binding partners such as zonula occludens-1 (ZO-1) [151–153], ZO-2 [154], afadin (also known as AF-6) [61, 151, 154], partitioning-defective 3 homolog (PAR-3) [155, 156], multi-PDZ domain protein 1 (MUPP1) [113], protein interacting with C kinase 1 (PICK-1) [157], calcium/calmodulin-dependent serine protein kinase (CASK) [158, 159], Rap guanine nucleotide exchange factor 6 (RAPGEF6/PDZ-GEF2) [61], and factor 2 (RAPGEF2/PDZ-GEF1) [154] belong to the group of PDZ domain-containing proteins that bind directly with F11R/JAM-A. Furthermore, in endothelial cells, monomeric F11R/JAM-A is incorporated by tetraspanin CD9 to F11R/JAM-A-CD9-αvβ3 integrin complex [160]. After the basic fibroblast growth factor (bFGF) stimulation, F11R/JAM-A is released from the developed complex and acts as a regulator of angiogenesis, endothelial cell migration, and MAPK (mitogen-activated protein kinase) activation. It is suggested that an unidentified cytoplasmic PDZ domain protein mediates the interaction of F11R/JAM-A with CD9 [160]. Besides, in different types of cells, four phosphorylation sites (Y280, S284, S287, S296) in the human F11R/JAM-A cytoplasmic domain have been hitherto identified experimentally [161–164], but only two of them (Tyr280, Ser284) have a known function (Fig. 2a) [77, 81, 165, 166]. To sum up, the cytoplasmic region of F11R/JAM-A participates in the TJ assembly [28], intracellular signaling pathways [30, 57, 62, 167], and cell polarity regulation [30, 168].

**F11R/JAM-A expression in cancer**

Around 90% of human carcinomas originate from epithelial tissues. For many years, it was thought that the loss of proteins associated with TJs is required in the early stages of the cancer metastasis (epithelial intercellular adhesion disturbances) [34, 169–173]. Meanwhile, in some cases, overexpression of TJ proteins is related to the regulation of intracellular signaling cascades responsible for tumorigenesis and metastasis [15]. Therefore, an imbalance in the F11R/JAM-A expression may result in pathological consequences and disorders in the normal cell function. F11R/JAM-A participation in cancer progression and invasiveness is still a debated issue. Hitherto, the effects of aberrant F11R/JAM-A expression and its potential mechanisms in
breast cancer have been best studied [131–142]. Of note, there have also been reports of its contribution to the development of many other malignancies [66, 87, 88, 105–130]. In this review, we focus on the dysregulation of a TJ protein, namely F11R/JAM-A, and its contribution to human cancer progression and metastasis. Figure 3 illustrates current knowledge about the mechanisms by which F11R/JAM-A affects tumorigenesis. The correlation between the F11R/JAM-A expression level in different carcinomas and poor prognosis in patients is summarized in Table 2.

**Breast cancer**

The F11R/JAM-A role in breast cancer progression and metastasis remains a controversial issue. In 2008, the first published evidence indicated that in breast tumor metastases, F11R/JAM-A expression is decreased versus in normal human mammary epithelium [135]. According to Naik et al. [135], in breast cancer cell lines, downregulation of F11R/JAM-A protein correlates with an increased ability to cell migration, which is required for tumor cell invasion and metastasis. High F11R/JAM-A amounts were observed on the surface of cells showing less ability to migrate (T47D, MCF-7, and MDA-MB-468, respectively), whereas low F11R/JAM-A level was found on MDA-MB-231 cells, which is marked by high migratory potential. In MDA-MB-231 cells, migration and invasion were suppressed by F11R/JAM-A overexpression. Additionally, enhanced invasiveness of highly migratory cells was observed after F11R/JAM-A knockdown through the use of short interfering RNAs. Authors provide evidence that a possible mechanism responsible for cell migration blockade via F11R/JAM-A is associated with the cytoskeletal rearrangement, directly with an increased stable focal adhesion formation [135].

Shortly afterward, two research groups showed contradictory results. Their studies demonstrated that poor prognosis in breast cancer patients correlates with F11R/JAM-A overexpression [131, 132, 134]. Indeed, recurrence (within five years) occurs in patients whose tumors had high F11R/JAM-A expression levels [132]. McSherry et al. [132] and Murakami et al. [131] observed a strong correlation between high F11R/JAM-A level and reduced patient survival after

---

![Fig. 3 Schematic overview of the signaling pathways by which F11R/JAM-A affects tumorigenesis. The F11R/JAM-A function in cancer progression is not only associated with the regulation of cell migration but also with an influence on apoptosis, epithelial-to-mesenchymal transition (EMT), cancer stem cell maintenance (self-renewal and pro-survival factor), and cell proliferation. AF-6 afadin, Akt, protein kinase B, β1-integrin, F11R/JAM-A, GATA3, Her2, JNK, MEK, MEK-ERK signaling, NFκB, PI3K, Raf, Rap guanine nucleotide exchange factor 6, Raf-kinase, Rap guanine nucleotide exchange factor 6, Raf serine/threonine-protein kinase, Raf serine/threonine-protein kinase, Raf small GTPase, TGF-β1 transforming growth factor-beta 1](image-url)

---

Adhesion molecule-A, GSK3 α/β glycogen synthase kinase 3, α and β isoforms, HER2, human epidermal growth factor receptor-2, JNK, c-Jun N-terminal kinase, MAPK, mitogen-activated protein kinase, MEK serine/threonine/threonine kinase, NFKB nuclear factor kappa B, PDZ-GEF2 Rap guanine nucleotide exchange factor 6, PI3K phosphoinositide 3-kinase, RAF serine/threonine-protein kinase, RAS small GTPase, TGF-β1 transforming growth factor-β1
the analysis of 270 and 444 breast tumor samples. The divergence of data may be related to the fact that Naik et al. [135], in their research, used only 62 cases of commercial tumor tissue microarrays (including 12 low-grade tumors, and 50 malignant primary breast tumors). F11R/JAM-A upregulation in tumor tissues from various origins (including breast cancer) versus normal tissues was also revealed by Goetsch et al. [137].

Moreover, McSherry et al. [132] emphasized that the possible mechanism of attenuated breast cancer cell motility after F11R/JAM-A loss is associated with a β1-integrin level reduction. Based on the invasive breast cancer tissue microarray analysis, it was shown that the increase in β1-integrin expression, one of the proteins required for cell migration, was associated with poor clinical outcomes in breast cancer patients [132, 141]. In mouse breast cancer models, proliferation and formation of metastases were also associated with the β1-integrin level [174, 175]. In further studies, identification of the F11R/JAM-A signaling events regulating β1-integrin-dependent migratory activity has shown that F11R/JAM-A could indirectly activate Rap1 GTPase via AF-6 and PDZ-GEF2 proteins through complex formation [133]. Rap1 GTPase is an activator of β1-integrins and a regulator of breast tumorigenesis. These findings have confirmed the F11R/JAM-A role in the cancer cell migration enhancement through Rap1 GTPase and β1-integrin activation and provide the evidence that it could be a novel therapeutic target in breast cancer patients for the development of anti-migratory cancer therapies and a negative prognostic factor for murine and human mammary tumor growth [131, 133].

The F11R/JAM-A function in cancer progression is not only associated with the regulation of cell migration but also with an influence on apoptosis and proliferation [131, 134, 137, 140]. Wang and Liu [140] revealed the link between the F11R/JAM-A expression and transforming growth factor-β1 (TGF-β1) signaling in the regulation of breast cancer cell proliferation and invasion. They proposed the following mechanisms by which TGF-β1 controls F11R/JAM-A expression by distinct signaling pathways: the TGF-β1-stimulated F11R/JAM-A gene transcription via Smad-mediated signaling cascade and activation of p54

| Cancer type          | F11R/JAM-A expression | Correlation with poor prognosis | References |
|----------------------|-----------------------|---------------------------------|------------|
| Breast cancer        | ↓, ↑                  | +                               | [131, 132, 134, 135, 139, 142, 176] |
| Gastric cancer       | ↓                     | −                               | [114]      |
| Pancreatic cancer    | ↓                     | −                               | [111]      |
| Nasopharyngeal cancer| ↑, ↓                  | +                               | [88, 117, 125] |
| Lung cancer          | ↑                     | +                               | [121, 129, 130] |
| Glioblastoma         | ↑                     | +                               | [120, 123] |
| Epithelial ovarian cancer | ↑                 | +                               | [116]      |
| Endometrial carcinoma| ↓                     | −                               | [118]      |
| Uterine adnexa cancer| ↓                     | −                               | [87]       |
| Multiple myeloma     | ↑                     | +                               | [124, 178, 179] |
| Lymphoma             | ↑                     | +                               | [128]      |
| Oral squamous cell carcinoma | ↑     | +                               | [127]      |
| Renal cell carcinoma | ↓                     | 0                               | [112]      |
| Cervical adenocarcinoma | ↑               | Unknown                         | [108]      |
| Head and neck squamous cell cancer | ↑ | Unknown                         | [105, 119] |
| Anaplastic thyroid cancer | ↓     | Unknown                         | [122]      |
| Testicular cancer    | ↑                     | Unknown                         | [66]       |
| Salivary gland tumor | ↑                     | Unknown                         | [109]      |
| Colorectal cancer    | Unknown               | Unknown                         | [110]      |
| Melanoma             | Unknown               | Unknown                         | –          |

(↑) higher F11R/JAM-A expression in cancer cells in comparison to normal tissue; (↓) lower F11R/JAM-A expression in cancer cells in comparison to normal tissue; (+) positive correlation between F11R/JAM-A expression and poor clinical outcome; (−) negative correlation between F11R/JAM-A expression and poor clinical outcome; (0) no prognostic value revealed

\(^{a}[135]\)

\(^{b}[117]\)
translational regulation of F11R/JAM-A protein degradation (through clathrin-mediated endocytosis) [140]. Another mechanism of action is associated with the fact that F11R/JAM-A acts as a survival factor for mammary carcinoma cells by protecting tumor cells from apoptosis. The F11R/JAM-A-mediated anti-apoptotic activity may correlate with changes in β1-integrin levels, which can also transmit anti-apoptotic signals. Increasing breast cancer cell susceptibility to apoptosis and reduction of aggressive tumor behavior are associated with F11R/JAM-A loss [131].

Interestingly, subsequent investigations revealed that aggressive breast cancer phenotypes are characterized by F11R/JAM-A and human epidermal growth factor receptor-2 (HER2) overexpression. Brennan et al. [134] speculate that F11R/JAM-A regulates HER2 proteasomal degradation and activity in vitro and may potentially be an oncotarget in HER2-positive breast cancers. In line with this model, the F11R/JAM-A upregulation enhances proliferation and reduces apoptosis through HER2 signaling by the PI3K (phosphoinositide 3-kinase) and MAPK pathways [137]. A recent study showed that the F11R/JAM-A extracellular domain cleavage co-occurring with the F11R/JAM-A overexpression correlates with the induction of resistance to HER2-targeted drugs. In semi in vivo and in vitro breast cancer models, invasive potential of cancer cells was intensified by cleaved F11R/JAM-A [139]. Moreover, Cruz et al. [142] studies showed that F11R/JAM-A also regulates HER3 expression through a pathway involving the transcription factors β-catenin and FOXA1. In vivo murine studies have confirmed the F11R/JAM-A role in apoptosis and breast tumor proliferation [131, 137]. Increased apoptosis in mice without F11R/JAM-A was associated with smaller tumors [131]. Another investigation elucidated that a specific anti-F11R/JAM-A monoclonal antibody reduced murine breast tumor xenograft growth [137]. Bednarek et al. demonstrated that the F11R/JAM-A protein can be considered as a novel target in the treatment of breast cancer metastasis and suggested the role of F11R/JAM-A-derived peptide as a possible anti-metastatic drug [136].

F11R/JAM-A expression is regulated by microRNAs. Reduced F11R/JAM-A expression and breast cancer cell motility as well as invasiveness are modulated by the enhanced miR-145 expression [138]. Of note, breast cancer cell lines and clinical samples characterize miR-145 downregulation [138]. Conversely, miR-495 upregulation in breast cancer tissue specimens and F11R/JAM-A as its potential target were proved. Migration of cancer cells induced by miR-495 is associated with high F11R/JAM-A level [176].

To sum up, despite a great body of evidence on the F11R/JAM-A functional role in breast cancer progression and metastasis, its mechanisms of action in this malignancy have not been fully elucidated. Initially, the invasion of breast cancer cells was shown to be induced by the F11R/JAM-A downregulation [135, 176]. However, breast cancer clinical datasets analysis demonstrated that its overexpression is strongly correlated with cancer patients’ poor prognosis [131, 132, 134, 139, 142].

**Gastric cancer**

In 2020, gastric cancer was the fourth leading cause of cancer-related death and the fifth most prevalent malignancy worldwide [177]. The multipronged analysis showed F11R/JAM-A underexpression as a prognostic factor predicting poor clinical outcomes and enhanced tumor aggressiveness in gastric cancer patients [114]. Low F11R/JAM-A expression level in gastric cancer promotes tumor cell invasion and migration, but not proliferation, and contributes to large tumor size, lymphatic vessel invasion, lymph node metastasis, and advanced TNM Classification of Malignant Tumors stage. Unfortunately, the molecular mechanism involved in the described F11R/JAM-A biological actions was not defined [114]. A year later, Ikeo et al. [115] demonstrated attenuated proliferation and invasion of a rat gastric cancer-like cell line (RGK1) after F11R/JAM-A dampening. Similar results were obtained in a human gastric cancer cell line (NCI-N87); an additional observation was a diminished anti-apoptotic protein Bcl-xL expression. F11R/JAM-A knockdown did not change the AKT and Mcl-1 protein expression. Conclusively, F11R/JAM-A plays an essential role in gastric cancer progression through suppressed apoptosis and enhanced proliferation of cancer cells [115].

**Pancreatic cancer**

Pancreatic cancer is a highly aggressive tumor. F11R/JAM-A could be a prognostic value in cancer progression because its low expression level negatively correlates with the presence of distant metastasis, histologic grade, and positive lymph node status. F11R/JAM-A depletion in pancreatic cancer tissue specimens related to poor overall patient survival calculated by the Kaplan–Meier method. Because the F11R/JAM-A expression level was determined retrospectively by immunohistochemistry, more detailed studies should be performed to confirm the data mentioned above [111].

**Nasopharyngeal carcinoma**

Metastasis and invasiveness of various cancers depend on the conversion of epithelial cells into mesenchymal cells. In human nasopharyngeal carcinoma (NPC), the F11R/JAM-A overexpression acts as an epithelial–mesenchymal transition inducer by the PI3K/Akt pathway activation. Additionally, the analysis of 172 patients with NPC showed that the F11R/JAM-A upregulation correlates with poor
prognosis and metastasis [88]. Based on the findings that the F11R/JAM-A expression could be regulated via micro-RNAs, Jiang et al. [117] recently reported that miR-543 is significantly higher expressed in NPC cell lines and tissues, and its upregulation enhances proliferation and invasion of cancer cells. The overexpression of F11R/JAM-A impeded the miR-543-induced proliferation of NPC cells suggesting that miR-543/F11R/JAM-A signaling plays a critical role in progression. Moreover, the results showed that the F11R/JAM-A underexpression elevated migration. In NPC tissues and cell lines, a reduced F11R/JAM-A expression was indicated in comparison to the normal control group [117]. The obtained data were not consistent with earlier studies conducted by Tian et al. [88]. In parallel, it was shown that the miR-124 overexpression intensified radiosensitivity and suppressed stem-like properties of cancer cells through F11R/JAM-A targeting. In NPC tissues, miR-124 downregulation and correlation with patient poor overall survival were revealed [125].

**Lung cancer**

In patients with non-small cell lung cancer (NSCLC), F11R/JAM-A is mainly expressed in cell membranes. Its overexpression occurred in 37% of lung tumor specimens and correlated with advanced TNM stage, lymph node metastasis, and diminished NSCLC patient survival. In some types of NSCLC cell lines, a high F11R/JAM-A amount was also observed. It induced NSCLC cell proliferation through cell cycle regulation. F11R/JAM-A suppression promotes the cell cycle arrest at the G1/S boundary, thereby decreases cancer cell proliferation and tumor growth. Its loss was accompanied by depletion in the amount of cell cycle-related proteins, such as cyclin D1, CDK4, 6, and P-Rb. F11R/JAM-A overexpression positively correlated with tumor aggressiveness and NSCLC progression [129].

F11R/JAM-A upregulation was also observed in lung adenocarcinoma and atypical adenomatous hyperplasia of lung. Knockdown of F11R/JAM-A was associated with intensified apoptosis of cancer cells, reduced in vivo tumorigenicity, attenuated colony-forming ability, decreased motility and invasiveness of cells, while increased expression was related to neoplasia occurrence [121]. Consistently, in lung adenocarcinoma patients cohort investigated by Zhao et al. [130], the upregulation of F11R/JAM-A and its influence on poor overall survival and high mortality rate were also indicated.

**Glioblastoma**

Glioblastomas are highly resistant to radiotherapy and chemotherapy. In glioblastomas (GBM), F11R/JAM-A overexpression correlates with shorter patient survival and overall poor outcome [120]. Further, F11R/JAM-A could be involved in cancer aggressiveness, in low-grade gliomas versus glioblastomas, and its level was significantly lower. The connection between patient survival and the F11R/JAM-A level in grade II and III gliomas was not detected, maybe because of a small patient number used in studies [123]. In previous research, it was proved that F11R/JAM-A is a prognostic factor in glioblastomas [120].

**Ovarian cancer**

Recently, the clinical significance of F11R/JAM-A gene expression was assessed by Boljevic et al. [116] in epithelial ovarian cancer (EOC), the most aggressive and frequent ovarian cancer type. Obtained results showed that patients with F11R/JAM-A overexpression tend to have worse overall survival versus patients with F11R/JAM-A depletion. Furthermore, an unfavorable clinicopathological feature in EOC is related to advanced International Federation of Gynecologists and Obstetricians (FIGO) stage, peritoneal metastasis, residual tumor, and high F11R/JAM-A expression, suggesting the F11R/JAM-A involvement in tumor aggressiveness. Further studies are required to elucidate molecular mechanisms responsible for the observed F11R/JAM-A role in EOC [116].

**Endometrial carcinoma**

In human endometrial carcinoma, the F11R/JAM-A expression is negatively correlated with poor patient prognosis (histologic grade, myometrial invasion, and stage). F11R/JAM-A underexpression in high-grade and advanced endometrial cancers is associated with invasiveness and low overall patient survival and progression-free survival rates. Furthermore, in studies on 3D-cultured endometrial carcinoma cells, the reduced F11R/JAM-A expression in poorly differentiated (KLE cell line) versus well-differentiated adenocarcinoma (Ishikawa cell line) was confirmed [118].

**Uterine adnexa carcinoma**

High-grade serous carcinoma of uterine adnexa (HGSC) is an epithelial ovarian malignancy histotype. Poorer patient clinical outcome (shorter progression-free survival and overall survival) correlated with F11R/JAM-A underexpression in all tested cohorts composed of 1526 cases. The data reliability is confirmed by a large number of cases studied and the observed reproducibility of obtained results. Furthermore, flow cytometric analysis of twenty-six human uterine cancer-derived cell lines determined F11R/JAM-A as a potential new prognostic biomarker. In this study, intensified EMT was demonstrated in tumors with the low F11R/JAM-A expression, which means that the EMT-dependent
mechanism could be responsible for this effect [87]. Cancer progression via EMT initiation has been observed also in nasopharyngeal cancer and head and neck squamous cell carcinoma.

**Multiple myeloma**

Multiple myeloma (MM) is a hematological malignancy, which is characterized by the uncontrolled clonal plasma cell proliferation. One of the mechanisms of cancer cell survival and drug resistance development is cell adhesion. First published studies concerning the F11R/JAM-A expression in MM patients reported high F11R/JAM-A expression in primary cells and cancer cell lines (RPMI-8226, U266, NCI-H929, LP-1, KMS-12-BM, SKMM-2, OPM-2). Patients with F11R/JAM-A upregulation were characterized by worse outcomes within six years [178]. Three years later, Solimando et al. [124] confirmed the overexpression of F11R/JAM-A in several MM cell lines (RPMI 8226, U266, OPM-2, NCI-H929) and 147 biopsies and bone marrow from cancer patients. Poor clinical prognosis correlated with elevated F11R/JAM-A levels in the MM plasma cell surface. Also, the concentration of circulating soluble F11R/JAM-A in serum was intensified in comparison with healthy individuals. In vitro studies revealed that F11R/JAM-A blocking disturbed MM cell migration, proliferation, viability, colony formation, and chemotaxis. Besides, an anti-F11R/JAM-A monoclonal antibody treatment inhibited tumor progression in vivo in MM-bearing mice. Taken together, F11R/JAM-A was proposed as a potential novel therapeutic target against MM [124]. Up-to-date data showed that F11R/JAM-A directly mediates MM progression via angiogenesis enhancement. Furthermore, in newly diagnosed and relapsed MM patients, high F11R/JAM-A surface expression on bone marrow-derived endothelial cells (BM-ECs) associates with poor clinical outcomes and survival. Diminished MM progression and vascularity were attained after F11R/JAM-A blocking on BM-ECs [179].

**Lymphoma**

In diffuse large B-cell lymphoma patients with multiple extranodal lesions, F11R/JAM-A overexpression relation to EMT and cancer cell invasion in vitro and also in vivo were indicated. Regarding the underlying mechanism, the high F11R/JAM-A level initiated the TGF-β/NODAL signaling, whereby prompted increased cancer cell aggressiveness. Furthermore, patients with F11R/JAM-A upregulation had a poor prognosis, including shorter progression-free survival and lower complete remission rate [128]. Interestingly, in breast cancer, TGF-β signaling is also involved in cancer progression through F11R/JAM-A participation.

**Oral cancer**

Recently, the F11R/JAM-A protein expression was investigated by Upadhaya et al. [127] in oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC). Revealed F11R/JAM-A overexpression was related to cancer cell perineural invasion, aggressive histological tumor grades, and correlated with a low survival rate in comparison to cancer patients with F11R/JAM-A underexpression. The authors suggested that the dimerization mechanism is responsible for the high F11R/JAM-A level. In most OSCC tissues, F11R/JAM-A was delocalized to the cytoplasm from the cell membrane [127].

**Renal cell carcinoma**

In the human kidney, F11R/JAM-A is expressed in the distal convoluted tubule, connecting tubule, collecting duct cells, and weakly expressed in proximal tubule cells. In 282 biopsies from renal cell carcinoma (RCC) patients, the F11R/JAM-A underexpression and enhanced cancer cell migration were demonstrated, which means that this protein contributed to RCC progression. The RCC4 cell line migration was promoted by the F11R/JAM-A inhibition. Metalloproteinase-mediated F11R/JAM-A downregulation in HK-2 cells was induced after the pro-inflammatory cytokine (interferon-γ and tumor necrosis factor-α) treatment. The downregulation of F11R/JAM-A in RCC could be caused by enhanced metalloproteinase shedding. Any correlation with poor prognosis in RCC patients was not demonstrated. The performed analysis confirmed only a trend to a positive correlation with tumor grade. Nonetheless, F11R/JAM-A expression in biopsies of patients with clear cell renal cell carcinoma is associated with primary tumor category and tumor grade [112].

**Cervical adenocarcinoma**

The expression of F11R/JAM-A and claudin-1, 4, 7 proteins is significantly upregulated in patients with cervical adenocarcinoma and adenocarcinoma in situ (AIS). Based on immunoreactivity, Akimoto et al. [108] indicated that F11R/JAM-A or claudin-1 could be used as biomarkers for distinguishing cervical adenocarcinoma from non-neoplastic glands with high sensitivity (F11R/JAM-A with a higher rate) and specificity (both at the same rate) [108].

**Head and neck squamous cell carcinoma**

In head and neck squamous cell carcinoma (HNSCC), the F11R/JAM-A overexpression was revealed. All HNSCC differentiated stages (well, moderately, poorly) are characterized by high F11R/JAM-A mRNA expression. The
plasma-soluble F11R/JAM-A level in HNSCC patients’ serum was also high, which means that it could be a serum diagnostic marker of HNSCC [105, 119]. In further in vitro studies, the F11R/JAM-A dysregulation mechanism through the p63/GATA-3 was proved. In theDetroit562 cell line, F11R/JAM-A overexpression is also observed. Knockdown of F11R/JAM-A suppressed proliferation, migration, and invasion of cells [105].

**Thyroid carcinoma**

In anaplastic thyroid carcinoma (ATC) versus tissues from papillary thyroid cancer and normal thyroid, F11R/JAM-A underexpression was proved by the EMT-PCR array of 84 EMT-related genes. The observed downregulation was associated with tumor size, extrathyroid infiltration, and ATC histological type. In vitro studies, cancer cell proliferation, transendothelial migration, and motility were dampened after the restoration of the F11R/JAM-A protein level. Noteworthy, the F11R/JAM-A overexpression was associated with an increased level of p53 and GSK3 α/β proteins phosphorylation. Regulation of GSK3 α/β and p53 signaling pathways through the F11R/JAM-A protein attenuates thyroid cancer cell aggressiveness [122]. Enhanced cancer cell proliferation and apoptosis inhibition by PI3K/Akt signaling pathway were determined also in breast cancer.

**Testicular cancer**

The F11R/JAM-A protein is present in spermatogonia and spermatocytes in the normal human testis and at inter-Sertoli cell tight junctions. It is overexpressed in seminoma cells, which may suggest that it promotes cancer cell migration and infiltration. In tubules with testicular carcinoma in situ, the F11R/JAM-A location is disorganized [66].

**Salivary gland tumor**

Salivary gland tumors (SGTs) are a comparatively rare disease, approx. 75% of which are not malignant tumors. Immunohistochemistry of 77 specimens of human SGTs and 40 non-tumorous tissues revealed the high F11R/JAM-A expression in ductal epithelium tumor cells compared to normal tissues. In malignant SGTs, claudin-4 and F11R/JAM-A are potential targets for molecular therapy [109].

**Colorectal cancer**

Severson’s et al. [61] findings demonstrate that F11R/JAM-A regulates human colonic epithelial cell migration through the F11R/JAM-A dimerization-mediated signaling. F11R/JAM-A dimerization facilitates the formation of a signaling complex (containing AF-6 and PDZ-GEF2), which in turn activates Rap1-GTPase, thereby elevating β1-integrin levels and enhancing epithelial cell migration [61]. Nava et al. [180] observed in their in vitro and in vivo studies that the F11R/JAM-A loss correlates with intensified intestinal epithelial cell proliferation in a dimerization-dependent manner, through the enhancement of Akt-dependent β-catenin activation. Whereas, in F11R/JAM-deficient mice, Akt inhibition reversed intestinal hyperproliferation. The authors reported that PI3K- and PTEN-dependent, Akt-mediated β-catenin transcriptional activation are required for increased cell proliferation [180]. Similar signaling pathways are involved in breast cancer progression through F11R/JAM-A.

Colorectal cancer is one of the deadliest carcinoma types worldwide. Recent research of the involvement of F11R/JAM-A and LFA-1 genetic variants in colorectal cancer development and metastasis was the first investigation of these gene variations in patients [110]. The authors revealed that the F11R/JAM-A rs790056 variation could influence the development of colorectal carcinoma (CC genotype has a threefold increased risk of colorectal cancer occurrence) and suggested that this variation could be evaluated as a potential predictive biomarker of this cancer type. Unfortunately, they did not define the relationship between genotypes and F11R/JAM-A expression (protein expression and soluble F11R/JAM-A levels or mRNA were not measured) [110].

**Melanoma**

Malignant melanoma cells have high metastatic potential. Ghislin et al. [107] revealed that F11R/JAM-A has an inhibitory role in melanoma transendothelial migration in vitro. The authors also showed that JAM-C plays an opposite role in melanoma A375 cells. F11R/JAM-A inhibition leads to intensified SLM8 cell migration through endothelial cells. Conversely, JAM-C impaired this efficiency of A375 cells [107]. F11R/JAM-A and JAM-C expression in the skin was previously approved by other research groups [48, 181]. To date, the F11R/JAM-A expression level in normal versus melanoma tissues is still undefined.

**F11R/JAM-A immunological role in cancer**

F11R/JAM-A affects immune-mediated processes because it is also expressed on immune cells, such as lymphocytes, polymorphonuclear neutrophils (PMNs), monocytes, and dendritic cells [50, 182, 183]. Notably, its ability to influence leukocyte trafficking is important in the context of its therapeutic potential in several pathological conditions, including cancer. In vivo, F11R/JAM-A-null mice demonstrated enhanced dendritic cell migration to lymph nodes and activation of specific immunity [182]. However, the lack of F11R/JAM-A negatively regulates polarized PMNs.
 trafficking [50]. For polarized migration, F11R/JAM-A expression on PMN is essential [50, 75]. In a recent study, Bonilha et al. [184] showed that F11R/JAM-A present on the surface of dendritic cells regulates T helper differentiation via its influence on CD4+ T cell-DC interactions during T cell priming. These findings demonstrated an F11R/JAM-A importance in the regulation of immune responses in pathological conditions, such as cancer, autoimmune diseases, and inflammation, in which CD4+ T cells play dominant roles [184].

The above-mentioned mechanisms may play an important role in cancer surveillance through the immune system [183]. Murakami et al. [185] demonstrated intensified antitumoral immune response, in the pancreatic islet cell carcinoma induced by SV40 T-antigen expression in β cells (Rip1Tag2 mice), after genetic-mediated F11R/JAM-A depletion. A decrease in cancer growth and invasiveness was associated with reduced angiogenesis and also enhanced depletion. A decrease in cancer growth and invasiveness (Rip1Tag2 mice), after genetic-mediated F11R/JAM-A carcinoma induced by SV40 T-antigen expression in β cells (Rip1Tag2 mice), after genetic-mediated F11R/JAM-A depletion. A decrease in cancer growth and invasiveness was associated with reduced angiogenesis and also enhanced depletion. A decrease in cancer growth and invasiveness (Rip1Tag2 mice), after genetic-mediated F11R/JAM-A carcinoma induced by SV40 T-antigen expression in β cells (Rip1Tag2 mice), after genetic-mediated F11R/JAM-A depletion. A decrease in cancer growth and invasiveness was associated with reduced angiogenesis and also enhanced depletion. A decrease in cancer growth and invasiveness (Rip1Tag2 mice), after genetic-mediated F11R/JAM-A carcinoma induced by SV40 T-antigen expression in β cells (Rip1Tag2 mice), after genetic-mediated F11R/JAM-A depletion. A decrease in cancer growth and invasiveness was associated with reduced angiogenesis and also enhanced depletion. A decrease in cancer growth and invasiveness (Rip1Tag2 mice), after genetic-mediated F11R/JAM-A carcino

F11R/JAM-A may be a monocyte prognostic marker of glioblastoma (GBM). Its high expression in mononuclear cells is associated with high-grade GBM occurrence, which means that this protein is a prognostic factor predicting poor clinical outcomes in GBM cancer patients, independently of its molecular subtype [187]. F11R/JAM-A expression is different in bone marrow-derived monocytes than in microglia (significantly higher). Additionally, it was proved that brain-infiltrating macrophages acquire F11R/JAM-A expression in high-grade GBM (in vitro) and after bone marrow transplantation [187]. In the tumor microenvironment (TME), F11R/JAM-A expression is also high in cells like macrophages and microglia. Currently, there has been little literature concerning F11R/JAM-A protein in the immune TME [126, 187]. One recent study demonstrated a sex-specific F11R/JAM-A role in the GBM microenvironment [126]. Intensified tumor growth, cancer cell proliferation, and microglia activation (Fizz1 and Ifi202b anti-inflammatory gene overexpression) were observed in female mice with F11R/JAM-A deficiency. The crucial role of F11R/JAM-A in the female tumor microenvironment is to diminish microglial activation [126]. Taking into consideration F11R/JAM-A’s pivotal role in leukocyte trafficking, it is important to determine its significance in leukocyte infiltration into the tumor microenvironment, which may be used in cancer immunotherapy.

**F11R/JAM-A on cancer stem cells**

Cancer stem cells (CSCs) are tumor cells with stem cell-like attributes and intensified ability to self-renewal and tumor-initiation [188, 189]. Glioblastoma (GBM) was one of the first tumors on which the CSC role was investigated. In patient-derived GBM cells, it was proven that F11R/JAM-A protein is crucial for CSC maintenance (Fig. 3) [120]. F11R/JAM-A was identified on stem cell-like brain tumor-initiating cells, which means that it probably acts as a niche adhesion factor in glioblastoma and affects brain tumor-initiating cells’ oncogenic potential [123]. Moreover, Alvarado et al. [188] showed high expression of F11R/JAM-A in GBM CSCs in vitro (self-renewal and proliferation) as well as in vivo (tumor-initiation). MicroRNA-145 (miR-145) binds directly to F11R/JAM-A, suppressed it, and as a result attenuates self-renewal. Whereas, miR-145 is downregulated in GBM CSCs, which means that it is a negative regulator of F11R/JAM-A-mediated CSC maintenance. Reduced self-renewal after miR-145 implementation was associated with a decrease in stem cell markers expression (including NANOG, OCT4, and SOX2) and impaired Akt signaling. Additionally, high F11R/JAM-A levels in combination with low miR-145 levels were a prognostic factor of poor clinical outcome for GBM patients [188].

Similarly, in triple-negative breast cancer (TNBC) cells, F11R/JAM-A is significant in CSC self-renewal [190]. Its high expression was observed in the population of green fluorescence protein-positive (GFP+) MDA-MB-231 and HCC70 breast cancer cells and TNBC patient-derived xenograft aldehyde dehydrogenase-positive (ALDH+) CSCs in comparison to control cells (GFP− and ALDH−, respectively). Attenuated self-renewal was associated with F11R/JAM-A absence [190].

Taken together, the literature highlight an F11R/JAM-A pro-tumorigenic role in self-renewal and cellular differentiation stimulation.

**Concluding remarks and perspectives**

More than 20 years have passed since the discovery of F11R/JAM-A, even though this protein is still the subject of research interest. A growing body of evidence points to its role in tumorigenesis and metastasis. In the literature, the F11R/JAM-A implication in cancer progression remains a controversial issue. Its overexpression is demonstrated in breast cancer, glioblastoma, oral squamous cell carcinoma, ovarian cancer, head and neck squamous cell carcinoma, cervical adenocarcinoma, salivary gland...
tumor, testicular cancer, lymphoma, non-small cell lung cancer, and in multiple myeloma, oppositely, low expression levels are revealed in pancreatic, thyroid, endometrial, uterine adnexa, renal, and gastric cancers (Table 2). At the same time, inconsistent data have been published on the F11R/JAM-A expression in nasopharyngeal cancer. Above-mentioned reports confirm the tissue-specific regulation of F11R/JAM-A expression. Indeed, low as well as its high levels have been correlated with poor clinical outcome prognosis of patients with different cancer types, which revealed that the prognostic value is also tissue-specific (Table 2). The poor outcome has been correlated with high expression in breast, glioblastoma, multiple myeloma, and lung cancer, whereas low expression in pancreatic, gastric, and endometrial carcinomas. Pro-tumorigenic or anti-tumorigenic F11R/JAM-A function depends on carcinoma type and should be further clarified. Its role seems to be complex and remains unclear. Also, the mechanisms responsible for its aberrant expression in tumor tissues remain to be defined. Of note, the F11R/JAM-A ability to interact with several proteins through its PDZ domain-binding motif in the cytoplasmic tail could probably be responsible for its different function in carcinogenesis through its involvement in various cell signaling pathways (Fig. 3). It is suggested that cancer progression is intensified by F11R/JAM-A upregulation. Probably, enhanced integrin-mediated migratory events associate with the F11R/JAM-A involvement in the epithelial-to-mesenchymal transition. However, its downregulation could intensify cancer initiation process through cell polarity loss and impair TJ structure. To understand its role in cancer, it will be essential to identify signaling pathways that are activated or suppressed via the F11R/JAM-A protein.

Conclusively, TJ proteins, namely F11R/JAM-A, could be a potential molecular marker of several human carcinomas because of its aberrant expression involved in cancer progression. F11R/JAM-A identification as a direct target for therapeutic antibodies or peptides causes that it could be considered as a potential new target for cancer treatment.

Acknowledgements This work was supported by the Medical University of Lodz, Poland.

Author contributions Conception and design: all authors. Literature search: KCP. Analysis and interpretation of data: KCP. Manuscript writing: all authors. Approval of final article: all authors.

Data availability Not applicable.

Code availability Not applicable.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Keiper T, Santosu S, Nawroth PP, Orlova V, Chavakis T (2005) The role of junctional adhesion molecules in cell-cell interactions. Histol Histopathol 20:197–203
2. Friedl P, Mayor R (2017) Tuning collective cell migration by cell–cell junction regulation. Cold Spring Harb Perspect Biol 9:1–17. https://doi.org/10.1101/cshperspect.a029199
3. Tokuda S, Yu ASL (2019) Regulation of epithelial cell functions by the osmolality and hydrostatic pressure gradients: a possible role of the tight junction as a sensor. Int J Mol Sci 20:1–23. https://doi.org/10.3390/ijms20143513
4. Steinbacher T, Kummer D, Ebnet K (2018) Junctional adhesion molecule-A: functional diversity through molecular promiscuity. Cell Mol Life Sci 75:1393–1409. https://doi.org/10.1007/s00018-017-2729-0
5. Collins C, Nelson WJ (2015) Running with neighbors: coordinating cell migration and cell–cell adhesion. Curr Opin Cell Biol 36:62–70. https://doi.org/10.1016/j.cceb.2015.07.004
6. Pawson T, Nash P (2003) Assembly of cell regulatory systems through protein interaction domains. Science 300:445–452. https://doi.org/10.1126/science.1083653
7. Pawson T, Scott JD (1997) Signaling through scaffold, anchoring, and adaptor proteins. Science 278:2075–2080
8. Ball LJ, Kuhne R, Schneider-Mergener J, Oshchkinat H (2005) Recognition of proline-rich motifs by protein-protein-interaction domains. Angew Chem Int Ed Engl 44:2852–2869. https://doi.org/10.1002/anie.200400618
9. Manjunath GP, Ramanajam PL, Galande S (2017) Structure function relations in PDZ-domain-containing proteins: implications for protein networks in cellular signalling. J Biosci 43:155–171. https://doi.org/10.1007/s12038-017-9727-0
10. Zihni C, Mills C, Matter K, Balda MS (2016) Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol 17:564–580. https://doi.org/10.1038/nrm.2016.80
11. Van Itallie CM, Tietgens AJ, Aponte A, Gucek M, Cartagena-Rivera AX, Chadwick RS, Anderson JM (2018) MARCKS-related protein regulates cytoskeletal organization at cell-cell and cell-substrate contacts in epithelial cells. J Cell Sci 131:1–14. https://doi.org/10.1242/jcs.210237
12. Matter K, Balda MS (2003) Signalling to and from tight junctions. Nat Rev Mol Cell Biol 4:225–236. https://doi.org/10.1038/nrm1055
13. Sugita K, Kabashima K (2020) Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel diseases. J Leukoc Biol 107:749–762. https://doi.org/10.1002/JLB.5MR0120-230R
14. Rusu AD, Georgiou M (2020) The multifarious regulation of the apical junctional complex. Open Biol 10:190278. https://doi.org/10.1098/rsob.190278
15. Lееch AO, Cruz RG, Hill AD, Hopkins AM (2015) Paradigms lost—an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis. Ann Transl Med 3:184. https://doi.org/10.3978/j.issn.2305-5839.2015.08.01
16. Takano K, Kojima T, Sawada N, Himi T (2014) Role of tight junctions in signal transduction: an update. EXCLI J 13:1145–1162
17. Zihni C, Balda MS, Matter K (2014) Signalling at tight junctions during epithelial differentiation and microbial pathogenesis. J Cell Sci 127:3401–3413. https://doi.org/10.1242/jcs.145029
18. Balda MS, Garrett MD, Matter K (2003) The ZO-1-associated Y-box factor ZONAB regulates epithelial cell proliferation and cell density. J Cell Biol 160:423–432. https://doi.org/10.1083/jcb.200210020
19. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, Guan KL (2011) Angiomitin is a novel Hippo pathway component that inhibits Yap oncoprotein. Genes Dev 25:51–63. https://doi.org/10.1101/gad.200111
20. IkarI A, Watanabe R, Sato T, Taga M, Ohkuni T, Koizumi J, Kamekura R, Ogasawara N, Masaki T, Fuchimoto J, Obata K, Hirakawa S, Nomura K, Keira T, Miyata R, Fujii N, Tsutsumi H, Himi T, Sawada N (2013) Regulation of tight junctions in upper airway epithelium. Biomed Res Int 2013:947072. https://doi.org/10.1155/2013/947072
21. Balda MS, Matter K (2016) Tight junctions as regulators of tissue remodelling. Curr Opin Cell Biol 42:94–101. https://doi.org/10.1016/j.cceb.2016.05.006
22. Claverie-Martin F (2015) Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis: clinical and molecular characteristics. Clin Kidney J 8:656–664. https://doi.org/10.1093/ckj/sfv081
23. Martin TA, Jiang WG (2009) Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta 1788:872–891. https://doi.org/10.1016/j.bbamem.2008.11.005
24. Wittekindt OH (2017) Tight junctions in pulmonary epithelia during lung inflammation. Pflugers Arch 469:135–147. https://doi.org/10.1007/s00424-016-1917-3
25. Kojima T, Honda T, Ginhoux F, Egawa G (2019) The immunological anatomy of the skin. Nat Rev Immunol 19:19–30. https://doi.org/10.1038/s41577-018-0084-5
26. Sato T, Shibata W, Maeda S (2019) Adhesion molecules and tight junctions in chronic rhinosinusitis: the regulation of tight junctions by IFN-gamma and IL-4. J Allergy Clin Immunol 130(1087–1096):E10. https://doi.org/10.1016/j.jaci.2012.05.052
27. de Boer WL, Sharma HS, Buellemans SM, Hoogsteden HC, Lambrecht BN, Brauntsha GJ (2008) Altered expression of epithelial junctional proteins in atopic asthma: possible role in inflammation. Can J Physiol Pharmacol 86:105–112. https://doi.org/10.1139/y08-004
28. Samadi N, Kiems M, Untersmayr E (2018) The role of gastrointestinal permeability in food allergy. Ann Allergy Asthma Immunol 121:168–173. https://doi.org/10.1016/j.anai.2018.05.010
29. Mandell KJ, McCall IC, Parks CA (2004) Involvement of the junctional adhesion molecule-1 (JAM1) homodimer interface in regulation of epithelial barrier function. J Biol Chem 279:16254–16262. https://doi.org/10.1074/jbc.M309483300
30. Kamata N, Andrews RA, Nash A, Parks CA (2005) Junctional adhesion molecule 1 regulates epithelial cell morphology through effects on 1 integrins and rap1 activity. J Biol Chem 280:11665–11674. https://doi.org/10.1074/jbc.M412650200
31. Kojima T, Go M, Takano K, Kurose M, Ho Y, Kozumi J, Kamekura R, Ogawara N, Masaki T, Fuchimoto J, Obata K, Hirakawa S, Nomura K, Keira T, Miyata R, Fujii N, Tsutsumi H, Himi T, Sawada N (2013) Regulation of tight junctions in upper airway epithelium. Biomed Res Int 2013:947072. https://doi.org/10.1155/2013/947072
32. Claverie-Martin F (2015) Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis: clinical and molecular characteristics. Clin Kidney J 8:656–664. https://doi.org/10.1093/ckj/sfv081
33. Martin TA, Jiang WG (2009) Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta 1788:872–891. https://doi.org/10.1016/j.bbamem.2008.11.005
34. Wittekindt OH (2017) Tight junctions in pulmonary epithelia during lung inflammation. Pflugers Arch 469:135–147. https://doi.org/10.1007/s00424-016-1917-3
35. Sato T, Shibata W, Maeda S (2019) Adhesion molecules and tight junctions in chronic rhinosinusitis: the regulation of tight junctions by IFN-gamma and IL-4. J Allergy Clin Immunol 130(1087–1096):E10. https://doi.org/10.1016/j.jaci.2012.05.052
36. Rerknimitr P, Otsuka A, Nakashima C, Kabashima K (2017) The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen 37:14. https://doi.org/10.1186/s41232-017-0044-7
37. Samadi N, Kiems M, Untersmayr E (2018) The role of gastrointestinal permeability in food allergy. Ann Allergy Asthma Immunol 121:168–173. https://doi.org/10.1016/j.anai.2018.05.010
38. Kernn M, Buehler R, Steinweg S, Alrefai WA, Dudeja PK (2018) Pathophysiology of IBD associated diarrhea. Tissue Barriers 6:e1463897. https://doi.org/10.1080/21683708.2014.1463897
39. de Boer WL, Sharma HS, Buellemans SM, Hoogsteden HC, Lambrecht BN, Braunsthal GJ (2008) Altered expression of epithelial junctional proteins in atopic asthma: possible role in inflammation. Can J Physiol Pharmacol 86:105–112. https://doi.org/10.1139/y08-004
40. Landy J, Ronde E, English N, Clark SK, Hart AL, Knight SC, Ciclitira PJ, Al-Hassi HO (2016) Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer. World J Gastroenterol 22:3117–3126. https://doi.org/10.3748/wjg.v22.i11.3117
41. Sato T, Shibata W, Maeda S (2019) Adhesion molecules and pancreatitis. J Gastroenterol 54:99–107. https://doi.org/10.1007/s00535-018-1500-0
42. Kong Y, Naggert JK, Nishina PM (2018) The impact of adherens and tight junctions on physiological function and pathological changes in the retina. Adv Exp Med Biol 1074:545–551. https://doi.org/10.1007/978-3-319-75402-4_66
43. Oshima T, Miwa H (2016) Gastrointestinal mucosal barrier function and diseases. J Gastroenterol 51:768–778. https://doi.org/10.1007/s00535-016-1207-z

© Springer
Parazzoli D, Mottiek T, Latini R, Dejana E (2005) Junctional adhesion molecule-A-deficient polymorphonuclear cells show reduced diapedesis in periostitis and heart ischemia–reperfusion injury. Proc Natl Acad Sci USA 102(30):10634–10639. https://doi.org/10.1073/pnas.0500147102

Khandoga A, Kessler JS, Meissner H, Hanschen M, Corada M, Motoike T, Enders G, Dejana E, Krombach F (2005) Junctional adhesion molecule-A deficiency increases hepatic ischemia–reperfusion injury despite reduction of neutrophil transendothelial migration. Blood 106:725–733. https://doi.org/10.1182/blood-2004-11-4416

Naik MU, Caplan JL, Naik UP (2014) Junctional adhesion molecule-A suppresses platelet integrin alphaIIbbeta3 signaling by recruiting Csk to the integrin-c-Src complex. Blood 123:1393–1402. https://doi.org/10.1182/blood-2013-04-496232

Karshovska E, Zhao Z, Blanchet X, Schmitt MM, Bidzhekov K, Soehnlein O, von Hundelshausen P, Mattheij NJ, Cosemans JM, Megens RT, Koeppel TA, Schoder A, Hackeng TM, Weber C, Koenen RR (2015) Hyperreactivity of junctional adhesion molecule-A-deficient platelets accelerates atherosclerosis in hyperlipidemic mice. Circ Res 116:587–599. https://doi.org/10.1161/CIRCRESAHA.116.340035

Naik MU, Stalker TJ, Brass LF, Naik UP (2012) JAM-A protects from thrombosis by suppressing integrin alphaIIbbeta3-dependent outside-in signaling in platelets. Blood 119:3352–3360. https://doi.org/10.1182/blood-2011-12-397398

F Cooke VG, Naik MU, Naik UP (2006) Fibroblast growth factor-2 failed to induce angiogenesis in junctional adhesion molecule-A-deficient mice. Arterioscler Thromb Vasc Biol 26:2005–2011. https://doi.org/10.1161/01.ATV.0000234923.79173.99

Naik MU, Moussa SA, Parkos CA, Naik UP (2003) Signaling through JAM-1 and alphavbeta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphavbeta3 complex. Blood 102:2108–2114. https://doi.org/10.1182/blood-2003-04-1114

Naik TU, Naik MU, Naik UP (2008) Junctional adhesion molecules in angiogenesis. Front Biosci 13:258–262. https://doi.org/10.2741/2676

Kobayashi I, Kobayashi-Sun J, Kim AD, Pouget C, Fujita N, Suda T, Traver D (2014) Jam1a-Jam2a interactions regulate haematopoietic stem cell fate through Notch signalling. Nature 512:319–323. https://doi.org/10.1038/nature13623

Wu KZ, Li K, Galileo DS, Martin-DeLeon PA (2017) Junctional adhesion molecule A: expression in the murine epididymal tract and accessory organs and acquisition by maturing sperm. Mol Hum Reprod 23:132–140. https://doi.org/10.1093/molehr/gaw082

Fedea JP, Esk C, Mierzwa B, Stanyte R, Yuan J, Zheng H, Ebnen K, Yan W, Korblich JA, Gerlich DW (2016) MicroRNA-34a/449 controls mitotic spindle orientation during mammalian cortex development. EMBO J 35:2386–2398. https://doi.org/10.15252/embj.201694056

Lakshmi SP, Reddy AT, Naik MU, Naik UP, Reddy RC (2012) Effects of JAM-A deficiency or blocking antibodies on neutrophil migration and lung injury in a murine model of ALL. Am J Physiol Lung Cell Mol Physiol 303:L758–L766. https://doi.org/10.1152/ajplung.00107.2012

Communal L, Medrano M, Sircoulomb F, Paterson J, Kobel M, Rahimi K, Hoskins P, Tu D, Lheureux S, Oza A, Ailles L, Provencecher D, Rottapel R, Mes-Masson AM (2020) Low junctional adhesion molecule-A expression is associated with epithelial-to-mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adenca. Mod Pathol. https://doi.org/10.1038/s41379-020-0586-0

Torres-Flores JM, Arias CF (2015) Tight junctions go viral! Viruses 7:5145–5154. https://doi.org/10.3390/v7092865

Schmitt MM, Megens RT, Zernecke A, Bidzhekov K, van den Akker NM, Rademakers T, van Zandvoort MA, Hackeng TM, Koenen RR, Weber C (2014) Endothelial junctional adhesion molecule-A guides monocytes into flow-dependent predilection sites of atherosclerosis. Circulation 129:66–76. https://doi.org/10.1161/CIRCULATIONAHA.113.004149

Waki H, Liu B, Miyake M, Kato K, Hurphy D, Kasparov S, Pannek JF (2007) Junctional adhesion molecule-1 is upregulated in spontaneously hypertensive rats: evidence for a prohypertensive role within the brain stem. Hypertension 49:1321–1327. https://doi.org/10.1161/HYPERTENSIONAHA.106.085589

Babinska A, Azari BM, Salifu MO, Liu R, Jiang XC, Sobocka MB, Boo D, Al Khoury G, Deitch JS, Marmur JD, Ehrlich YH, Kornecki E, Babinska A (2010) Silencing of the F11R gene reveals a role for F11R/JAM-A in the migration of inflamed vascular smooth muscle cells and in atherosclerosis. Atherosclerosis 212:197–205. https://doi.org/10.1016/j.atherosclerosis.2010.04.014

Babinska A, Kedees MH, Athar H, Sobocki T, Sobocka MB, Ahmed T, Ehrlich YH, Hussain MM, Kornecki E (2002) Two regions of the human platelet F11-receptor (F11R) are critical for platelet aggregation, potentiation and adhesion. Thromb Haemost 87:712–721

Babinska A, Kedees M, Athar H, Ahmed T, Batuman O, Ehrlich YH, Hussain MM, Kornecki E (2002) F11-receptor (F11R/JAM) mediates platelet adhesion to endothelial cells: role in inflammatory thrombosis. Thromb Haemost 88:843–850. https://doi.org/10.1267/thb02110843

Babinska A, Kedees MH, Athar H, Batuman O, Ehrlich YH, Hussain MM, Kornecki E (2002) Two regions of the human platelet F11-receptor (F11R) are critical for platelet aggregation, potentiation and adhesion. Thromb Haemost 87:712–721

Babinska A, Azari BM, Salifu MO, Liu R, Jiang XC, Sobocka MB, Boo D, Al Khoury G, Deitch JS, Marmur JD, Ehrlich YH, Kornecki E (2007) The F11 receptor (F11R/JAM-A) in atherothrombosis: overexpression of F11R in atherosclerotic plaques. Thromb Haemost 97:272–281

Babinska A, Azari BM, Salifu MO, Liu R, Jiang XC, Sobocka MB, Boo D, Al Khoury G, Deitch JS, Marmur JD, Ehrlich YH, Kornecki E (2007) The F11 receptor (F11R/JAM-A) in atherothrombosis: overexpression of F11R in atherosclerotic plaques. Thromb Haemost 97:272–281

Babinska A, Clement CC, Przygodzki T, Talar M, Li Y, Braun M, Wzorek J, Swiatkowska M, Ehrlich YH, Kornecki E, Watala C, Salifu MO (2019) A peptide antagonist of F11R/JAM-A reduces plaque formation and prolongs survival in an animal model of atherosclerosis. Atherosclerosis 284:92–101. https://doi.org/10.1016/j.atherosclerosis.2019.02.014

Vetrano S, Danese S (2009) The role of JAM-A in inflammatory bowel disease: unmasking the ties that bind. Ann N Y Acad Sci 1165:308–313. https://doi.org/10.1111/j.1749-6632.2009.04045.x

Fang T, J, Lin YZ, Li RN, Ou TT, Wu CC, Tsai WC, Yen YH (2016) F11R mRNA expression and promoter polymorphisms in patients with rheumatoid arthritis. Int J Rheum Dis 19:127–133. https://doi.org/10.1111/1756-185X.12663
102. Padden M, Leech S, Craig B, Kirk J, Brankin B, McQuaid S (2007) Differences in expression of junctional adhesion molecule-A and beta-catenin in multiple sclerosis brain tissue: increasing evidence for the role of tight junction pathology. Acta Neuropathol 113:177–186. https://doi.org/10.1007/s00401-006-0145-x

103. Antar AA, Konopka JL, Campbell JA, Henry RA, Perdigoto AL, Carter BD, Pozzi A, Abel TW, Demody TS (2009) Junctional adhesion molecule-A is required for hematogenous dissemination of reovirus. Cell Host Microbe 5:59–71. https://doi.org/10.1016/j.chom.2008.12.001

104. Lai CM, Boehme KW, Pruijssers AJ, Parekh VV, Van Kaer L, Kelly K, Espitia CM, Zhao W, Wendlandt E (2015) Junctional Kakuki T, Kurose M, Takano K, Kondoh A, Obata K (2016) Dysregulation of junctional adhesion molecule-A via p63/GATA-3 in head and neck squamous cell carcinoma. Oncotarget 7:33887–33900

105. Antar AA, Konopka JL, Campbell JA, Henry RA, Perdigoto AL, Carter BD, Pozzi A, Abel TW, Demody TS (2009) Junctional adhesion molecule-A is required for hematogenous dissemination of reovirus. Cell Host Microbe 5:59–71. https://doi.org/10.1016/j.chom.2008.12.001

106. Kelly K, Espitia CM, Zhao W, Wendlandt E (2015) Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget 6:41275–41289

107. Ghisin S, Obino D, Middendorp S, Boggetto N, Alcaide-Lordian C, Deshayes P (2011) Junctional adhesion molecules are required for melanoma cell line transendothelial migration in vitro. Pigment Cell Melanoma Res 24:504–511. https://doi.org/10.1111/j.1755-148X.2011.00856.x

108. Akimoto T, Takasawa A, Murata M, Kojima Y, Takasawa K, Nojima M, Aoyama T, Hiratsuka Y, Ono Y, Tanaka S, Osanai M, Hasegawa T, Saito T, Sawada N (2016) Analysis of the expression and localization of tight junction transmembrane proteins, claudin-1, -4, -7, occludin and JAM-A, in human cervical adenocarcinoma. Histol Histopathol 31:921–931. https://doi.org/10.14670/HH-11-729

109. Aoyama T, Takasawa A, Murata M, Osanai M, Takano K, Hasegawa T, Sawada N (2018) Immunoreactivity patterns of tight junction proteins are useful for differential diagnosis of human salivary gland tumors. Med Mol Morphol 52:23–35. https://doi.org/10.1007/s00795-018-0199-6

110. Caykara B,alsaadoni H, Pence HH, Pence S, Yilmaz Aydogan H, Tastekin D (2019) Investigation of JAM-A (rs790056) and LFA-1 (rs8058823) gene variants in Turkish colorectal cancer patients. Turk J Gastroenterol 30:872–876. https://doi.org/10.5152/tjg.2019.19141

111. Feng D, Spizzo G, Mitterer M, Seebere A, Steurer M, Gastl G, Brosch I, Moser P (2012) Low expression of junctional adhesion molecule A is associated with metastasis and poor survival in pancreatic cancer. Ann Surg Oncol 19:4300–4306. https://doi.org/10.1245/s10434-012-2381-8

112. Gutwein P, Schramme A, Voss B, Abdel-Bakky MS, Doberstein K, Ludwig A, Altevogt P, Hansmann ML, Moch H, Kristensen B, Rich JN (2014) High-throughput flow cytometry screening reveals a role for junctional adhesion molecule A as a cancer stem cell maintenance factor. Cell Rep 6:117–129. https://doi.org/10.1016/j.celrep.2013.11.043

113. Magara K, Takasawa A, Osanai M, Ota M, Tagami Y, Ono Y, Takasawa K, Murata M, Hirohashi Y, Miyajima M, Yamada G, Hasegawa T, Sawada N (2017) Elevated expression of JAM-A promotes neoplastic properties of lung adenocarcinoma. Cancer Sci 108:2306–2314. https://doi.org/10.1111/cas.13385

114. Orlandella FM, Marinimel RO, Iervolino PLC, Auletta L, De Stefano AE, Ugolini C, Greco A, Mirabelli P, Pane K, Franzese M, Denaro M, Basolo F, Salvatore G (2019) Junctional adhesion molecule-A is down-regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and OSK3 alpha/beta pathways. Mol Carcinog 58:1185–1193. https://doi.org/10.1002/mc.23001

115. Rosager AM, Sorensen MD, Dahlrot RH, Boldt HB, Hansen S, Lathia JD, Kristensen BW (2017) Expression and prognostic value of JAM-A in gliomas. J Neurooncol 135:107–117. https://doi.org/10.1007/s00025-017-1755-2

116. Rothermel MG, Stolz T, Rosager AM, Hale J, Hitomi M, Gallagher J, Wu Q, Martin J, Vidal JG, Nakano I, Dahlrot RH, Hansen S, McLendon RE, Sloan AE, Bao S, Hjelmeland AB, Carson CT, Naik UP, Kristensen B, Rich JN (2014) High-throughput flow cytometry screening reveals a role for junctional adhesion molecule A as a cancer stem cell maintenance factor. Cell Rep 6:117–129. https://doi.org/10.1016/j.celrep.2013.11.043

117. Rosager AM, Sorensen MD, Dahlrot RH, Boldt HB, Hansen S, Lathia JD, Kristensen BW (2017) Expression and prognostic value of JAM-A in gliomas. J Neurooncol 135:107–117. https://doi.org/10.1007/s00025-017-1755-2

118. Solimando AG, Brandl A, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A, Stuhmer T, Mokhtari Z, Rudelius M, Dotterweich J, Bittrich M, Desantis V, Ebert R, Trerotoli P, Frassaniti MA, Rosenwald A, Vacca A, Einsele H, Jakob F, Beilhack A (2018) JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia 32:736–743. https://doi.org/10.1038/leu.2017.287

119. Tian Y, Tian Y, Tu Y, Zhang G, Xing Z, Lin J, Ai M, Mao Z, Zheng R, Yuan Y (2020) microRNA-124 inhibits stem-like properties and enhances radiosensitivity in nasopharyngeal carcinoma cells via direct repression of expression of JAM-A. J Cell Mol Med 00:1–12. https://doi.org/10.1111/jcmm.15177

120. Turaga SM, Silver DJ, Bayik D, Paouri E, Peng S, Lauko A, Alban TJ, Borjini N, Stanko S, Naik U, Keri RA, Connor JR, Barnholtz-Sloan JS, Rubin JB, Berens M, Davalos D, Lathia JD (2020) JAM-A functions as a female microglial tumor suppressor in glioblastoma. Neuro Oncol. https://doi.org/10.1093/neuonc/noaa148

121. Upadhyaya P, Barhoi D, Giri A, Bhattacharjee A, Giri S (2019) Joint detection of claudin-1 and junctional adhesion molecule-A
of the scaffolding protein ZO-1. J Biol Chem 286:43352–43360. https://doi.org/10.1074/jbc.M111.304089

154. Monteiro AC, Sumagin R, Rankin CR, Leoni G, Mina MJ, Reiter DM, Stehle T, Dermody TS, Schaefer SA, Hall RA, Nusrat A, Parkos CA (2013) JAM-A associates with ZO-2, afadin, and PDZ-GEF1 to activate Rap2c and regulate epithelial barrier function. Mol Biol Cell 24:2849–2860. https://doi.org/10.1091/mbc.E13-06-0298

155. Klaus Ebnet K, Suzuki A, Horikoshi Y, Hirose T, Meyer zu Monteiro AC, Sumagin R, Rankin CR, Leoni G, Mina MJ, Ozaki H, Ishii K, Arai H, Horiuchi H, Kawamoto T, Suzuki H, Iden S, Misselwitz S, Peddibhotla SS, Tuncay H, Rehder D, Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Moham...
180. Nava P, Capaldo CT, Koch S, Kolegraff K, Rankin CR, Farkas AE, Feasel ME, Li L, Addis C, Parkos CA, Nusrat A (2011) JAM-A regulates epithelial proliferation through Akt/beta-catenin signalling. EMBO Rep 12:314–320. https://doi.org/10.1038/embor.2011.16

181. Kirschner N, Poetzl C, von den Driesch P, Wladykowski E, Moll I, Behne MJ, Brandner JM (2009) Alteration of tight junction proteins is an early event in psoriasis: putative involvement of proinflammatory cytokines. Am J Pathol 175:1095–1106. https://doi.org/10.2353/ajpath.2009.080973

182. Cera MR, Del Prete A, Vecchi A, Corada M, Martin-Padura I, Motoike T, Tonetti P, Bazzoni G, Verme M, Gentili F, Bernasconi S, Sato TN, Mantovani A, Dejana E (2004) Increased DC trafficking to lymph nodes and contact hypersensitivity in junctional adhesion molecule-A–deficient mice. J Clin Invest 114:729–738. https://doi.org/10.1172/jci121231

183. Luissint AC, Williams HC, Kim W, Fleming S, Azcutia V, Hillgarth RS, Leary MNO, Denning TL, Nusrat A, Parkos CA (2019) Macrophage-dependent neutrophil recruitment is impaired under conditions of increased intestinal permeability in JAM-A-deficient mice. Mucosal Immunol 12:668–678. https://doi.org/10.1038/s41385-019-0143-7

184. Bonilha CS, Benson RA, Scales HE, Brewer JM, Garside P (2021) Junctional adhesion molecule-A on dendritic cells regulates Th1 differentiation. Immunol Lett 235:32–40. https://doi.org/10.1016/j.imlet.2021.05.001

185. Murakami M, Francavilla C, Torselli I, Corada M, Maddaluno L, Sica A, Matteoli G, Iliev ID, Mantovani A, Rescigno M, Cavallaro U, Dejana E (2010) Inactivation of junctional adhesion molecule-A enhances antitumoral immune response by promoting dendritic cell and T lymphocyte infiltration. Cancer Res 70:1759–1765. https://doi.org/10.1158/0008-5472.CAN-09-1703

186. Bonilha CS, Benson RA, Brewer JM, Garside P (2020) Targeting opposing immunological roles of the junctional adhesion molecule-A in autoimmunity and cancer. Front Immunol 11:602094. https://doi.org/10.3389/fimmu.2020.602094

187. Pong WW, Walker J, Wylie T, Magrini V, Luo J, Emnett RJ, Choi J, Cooper ML, Griffith M, Griffith OL, Rubin JB, Fuller GN, Piwnica-Worms D, Feng X, Hambardzumyan D, DiPersio JF, Mardis ER, Gutmann DH (2013) F11R is a novel monocyte prognostic biomarker for malignant glioma. PLoS ONE 8:e77571. https://doi.org/10.1371/journal.pone.0077571

188. Alvarado AG, Turaga SM, Sathyan P, Mulkearns-Hubert EE, Otvos B, Silver DJ, Hale JS, Flavahan WA, Zinn PO, Sinyuk M, Li M, Guda MR, Velpula KK, Tsung AJ, Nakano I, Vogelbaum MA, Majumder S, Rich IN, Latha JD (2016) Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling. Neuro Oncol 18:656–666. https://doi.org/10.1093/neuonc/nov196

189. Boman BM, Wicha MS (2008) Cancer stem cells: a step toward the cure. J Clin Oncol 26:2795–2799. https://doi.org/10.1200/JCO.2008.17.7436

190. Thiagarajan PS, Hitomi M, Hale JS, Alvarado AG, Otvos B, Sinyuk M, Stoltz K, Wiechert A, Mulkearns-Hubert E, Jarrar AM, Zheng Q, Thomas D, Egelhoff TT, Rich JN, Liu H, Latha JD, Reizes O (2015) Development of a fluorescent reporter system to delineate cancer stem cells in triple-negative breast cancer. Stem Cells 33:2114–2125. https://doi.org/10.1002/stem.2021

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.